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Abstract
Background: Colorectal cancer (CRC) is the second most frequent tumor in developed countries. Since survival from
CRC depends mostly on disease stage at the time of diagnosis, individuals with symptoms or signs suspicious of CRC
should be examined without delay. Many factors, however, intervene between symptom onset and diagnosis. This study
was designed to: 1) Describe the diagnostic process of CRC from the onset of first symptoms to diagnosis and treatment.
2) Establish the time interval from initial symptoms to diagnosis and treatment, globally and considering patient's and
doctors' delay, with the latter due to family physician and/or hospital services. 3) Identify the factors related to defined
types of delay. 4) Assess the concordance between information included in primary health care and hospital clinical
records regarding onset of first symptoms.
Methods/Design: Descriptive study, coordinated, with 5 participant groups of 5 different Spanish regions (Balearic
Islands, Galicia, Catalunya, Aragón and Valencia Health Districts), with a total of 8 acute public hospitals and 140 primary
care centers.
Incident cases of CRC during the study period, as identified from pathology services at the involved hospitals. A sample
size of 896 subjects has been estimated, 150 subjects for each participant group.
Information will be collected through patient interviews and primary health care and hospital clinical records. Patient
variables will include sociodemographic variables, family history of cancer, symptom perception, and confidence in the
family physician; tumor variables will include tumor site, histological type, grade and stage; symptom variables will include
date of onset, type and number of symptoms; health system variables will include number of patient contacts with family
physician, type and content of the referral, hospital services attending the patient, diagnostic modalities and results; and
delay intervals, including global delays and delays attributed to the patient, family physician and hospital.
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Discussion: To obtain a nonrestricted sample of patients with CRC we have minimized selection risk by identifying the
patients from pathology services. A greater constraint may be associated with information sources based on clinical
records. Due to inherent features of coordinated studies, it is important to standardize the collection of information.
Background
Colorectal cancer (CRC) is one of the most common can-
cers in Western countries. In Spain, CRC incidence and
mortality rates are close to the median values for Euro-
pean countries [1]. CRC survival rates in Spain are above
the European average for both men and women and are
greater for colon than for rectal cancer [2].
Survival of CRC patients depends mostly on their disease
stage at the time of diagnosis. Most patients will be alive
after 5 years if the tumor has not reached the intestinal
wall (stage I). This rate decreases to 60% if the tumor has
invaded regional lymph nodes (stage III) and to only 5–
15% if the neoplasm has metastasized (stage IV) [2]. Thus,
individuals with symptoms or signs suspicious of CRC
should be examined without delay; however, many are
not. Many aspects of the delay of diagnosis or treatment
are poorly understood. Delay in diagnosis or treatment
may be predictors of the stage and survival of CRC, but
these results are controversial [3-8]. The majority of stud-
ies on CRC are not recent, dealt with small and restricted
sample sizes and were limited to hospital settings.
Most studies use the term delay to describe the time
elapsed between onset of the first symptom to diagnosis
or treatment. Conceptually, diagnostic delay in cancer is a
complex process involving patient behavior, physician
attitudes, response of the health system, biology of the
tumor cells, and interaction between host and tumor.
Studies on delay tend to distinguish between patient and
health system delays:
1. Patient delay
There are a number of reasons why a patient, facing a sign
or symptom suspicious of malignancy, may decide not to
visit a doctor. The patient may not be aware of the impor-
tance of symptoms [9], may be embarrassed to consult
about them [9], may not relate them with the disease [10],
or may fear a possible cancer diagnosis [11]. A family his-
tory of cancer together with a negative attitude to the med-
ical profession can also be a reason for delay [12], as is a
previous history of anxiety or depressive illness [13] Addi-
tional factors may include patient age, civil and social sta-
tus, mistrust in doctors or lack of time to visit a physician
[14,15]. Among symptom types, anemia is most fre-
quently associated with longer delay [16,17], whereas
multiple symptoms are associated with shorter delay [13].
In addition, a constitutional syndrome has been associ-
ated with a diagnosis made in the hospital emergency
department, whereas low abdominal symptoms are more
common in patients who undergo elective surgery [18].
2. Family doctor delay
The general practitioner plays an active role in cancer diag-
nosis, participating in nearly 63% [19]. His or her style of
practice is important in recognizing CRC. A study on fam-
ily doctors' clinical management of patients with gastroin-
testinal symptoms found that one third of patients did not
have a physical examination, fewer than 50% underwent
a digital rectal examination, and at least 90% of hospital
referrals failed to include primary care findings [20]. Non-
specific symptoms, the absence of routine rectal examina-
tion, and patient reluctance to undergo rectal exploration
may increase delay [21,22].
3. Hospital delay
Factors described as possible contributors to delay include
specialist referrals' waiting lists, poor coordination, and
complementary examinations. About 65% of patients
affected by gastrointestinal tract cancers were initially
diagnosed by a hospital emergency department, and over
50% had visited their general practitioners while having
symptoms related to CRC [18].
It is clear that more information is needed on the effects
of delay on CRC. The factors associated with diagnostic
delay are poorly understood, regardless of whether they
are related to the patient, to the family doctor or to the
hospital setting. In Spain, several Regional Health Plans
have highlighted problems in continuity of care and have
advocated a reduction in time interval between suspicion
of cancer and diagnosis or treatment. To achieve these
objectives it is essential to know the characteristics of the
CRC diagnostic process, to identify the delays that may
occur at various stages, and to gain a better understanding
of the factors associated with each type of delay.
Objectives
1. To describe the diagnostic process of CRC from the
onset of first symptoms until diagnosis and initial treat-
ment in terms of initial symptoms and other symptoms
appearing prior to and during the diagnostic process.
Family doctor participation in diagnosis: Proportion of
cases diagnosed by the family doctor; visits per patient,
physical examinations; complementary tests requested
according to the nature of symptoms; type of referral to
specialist and clinical information included in the referral.BMC Cancer 2007, 7:86 http://www.biomedcentral.com/1471-2407/7/86
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Hospital specialist diagnostic procedures: hospital depart-
ment, type of hospital; complementary examinations and
their results (true positives and false negatives).
2. To establish the time intervals between first symptoms
and diagnosis and/or treatment:
Patient delay: Time interval from the onset of first symp-
toms of CRC to first contact with a doctor.
Health system delay, separated into three time periods:
from first contact with a doctor to referral to a specialist or
emergency department; from specialist visit to diagnosis;
and from diagnosis to treatment.
3. To identify factors associated with these delays:
Patient: sociodemographic variables; patient referred
symptoms; attitude towards symptoms; confidence in the
doctor; and family history of cancer.
Health system: primary care, including physical examina-
tion and clinical assessment by the family physician; and
specialist care, including access to diagnostic tests, referral
paths, type of hospital, type of department, number and
type of complementary examination tests and their
results.
Secondary objectives:
4. To evaluate the reliability and thoroughness of infor-
mation about symptoms from patient interviews and pri-
mary care and hospital records.
5. To describe the variability in delay between different
geographic areas and different hospitals included in the
study.
Methods
It is a descriptive and multicenter study in 5 participating
health districts in Spain (Balearic Islands, Galicia, Cat-
alunya, Aragón and Valencia), including 8 acute public
hospitals and 140 primary health centers. Information
will be collected from medical records and structured
interviews with patients.
Subjects will be incident cases with histologically verified
CRC (CIE9 153 and 154) diagnosed during 2006–07 in
the study hospitals; patients have to be registered with a
family doctor in the health center included in the study.
Exclusion criteria: Prevalent and/or recurrent cases;
patients with multiple tumors; and patients diagnosed at
private hospitals.
Cases will be identified by hospital pathologists. The doc-
tor responsible for that patient will be contacted and
informed of possible patient inclusion. Inclusion and
exclusion criteria will be verified in the hospital clinical
record, and written informed consent will be requested
from the patient. Interviews will be carried out mainly
during a patient's hospital stay, or at home if that is not
possible. The sample size necessary for the whole multi-
centric project should be a minimum of 896 individuals
to achieve the study objectives with an accepted 5% alpha
error and an accuracy of one-tenth of the observed relative
frequency of different variables. Moreover, the selected
sample size will allow us to estimate symptom duration,
despite the usual dispersion of a 'time' variable (usually a
standard deviation over the mean). In addition, this sam-
ple size will permit to us to achieve objective number 3, to
assess if delay is related to any of the described factors,
with an alpha error ≤ 0.05 and a power ≥ 80%. Having at
least 150 patients in each region will allow a precise esti-
mation of geographical variations.
The number of persons included must be increased to
1,000, due to the inevitable collection of secondary and
often incomplete information from primary care (PHC)
and hospital (HC) clinical records.
A preinclusion patient form will be designed to hold
patient pathology results together with exclusion criteria.
A data collection book (DCB) will be prepared to include
information about interviews, primary health care and
hospital clinical records. A pilot study with 15 patients in
each sub-project will be undertaken to standardize data
collection and solve any conflicts. We will also carry out a
training workshop for field workers and interviewers.
Patient interviews will be centered mainly on CRC symp-
toms, perceived attitudes to initial symptoms and demo-
graphic data. Each patient will be asked how long he/she
has been feeling unwell and the type of symptoms noted
[23]. Symptoms spontaneously mentioned by the patient
will be considered the initial symptoms for that patient
and the date recorded. The patient will be asked to indi-
cate whether he/she had experienced any additional
symptoms summarized in a check-list. Symptoms per-
ceived up to 2 years prior to the first consultation will be
considered. Nonsymptomatic patients will be recorded as
a casual finding. Information on examination test dates,
results and clinical departments involved will be collected
by reviewing medical records. Variables are summarized
in Table 1. The study has received written approval from
the Ethics Committee of Clinical Research of each partici-
pating region.
A database will be built with a unique numerical case code
for each patient and checked for errors. Identifiable
patient information will be kept dissociated. Each partici-BMC Cancer 2007, 7:86 http://www.biomedcentral.com/1471-2407/7/86
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pating group will periodically send the patient data collec-
tion book to the coordinator node for centralized data
entry. Number and reason for exclusion and missing cases
will be noted.
Objective 1. A descriptive analysis of the key variables of
the CRC diagnosis process will be presented as frequency
distribution and 95% CI, and as mean and median.
Objective 2. It will be detailed total time delay; patient
and health system delay and their contribution to total
delay.
Objective 3. The relationship between different types of
delay and the observed variables will be evaluated. The
Chi-Square test will be used for qualitative variables, and
Student's t test, ANOVA or non-parametric tests for quan-
titative variables. To assess the effect of the predictive var-
iables on delay times, a survival analysis will be
performed as proposed by Latour [24]. In contrast with
follow up studies measuring survival, no data will be cen-
sored. Survival curves will be calculated by the Kaplan
Meier method, and the log-rank test will be used to com-
pare curves. To assess the independent effect of variables
on delay times, a proportional risk analysis will be done
using Cox regression. At the same time, the adequacy of
performing a multiple level analysis, to evaluate the
effects due to hospital center and District Health Author-
ity, will be evaluated. Analysis will also be carried out sep-
arately for patients with cancers of the colon and rectum.
Objective 4. The thoroughness of symptom information
given by patients will be compared with information
obtained from the PHC and HC clinical records, and a fre-
quency distribution of variables in each of the different
sources of information will be presented.
Objective 5. The variability of different delay intervals will
be evaluated by comparing median times and the inter-
quartile range for the considered variables. Moreover, for
each variable the proportional time variance of the study
areas will be estimated, including hospitals with longer
and shorter delay times and a graphic analysis.
Table 1: Study measurements
Patient
Age, gender, civil status, education, family history of cancer, symptom perception, confidence in the family doctor, and number of consultations until 
the first contact and reason for it.
Tumour
- Site, hystological grade, TNM at diagnosis.
Clinical:
- First symptom, data of the first symptom and other symptoms.
Delay intervals:
Patient-delay:
- Time elapsed from the date the patient perceived the first symptom until the date of the first contact with a doctor as a result of the first 
symptom/s.
Health system-delay. This delay distinguishes the following phases:
- Time elapsed between the first contact with the health system (consultation with the family doctor, specialist, or emergency department) and until 
the date of referral to a specialist.-
- Time elapsed between referral to a specialist or emergency department and until the diagnosis. In this context diagnosis is understood as the date 
of the biopsy or direct surgery if that was the case.
- Time elapsed between diagnosis and treatment. In this context we consider surgical treatment. Failing on that chemotherapy or palliative care 
treatment as the first option.
Total delay: Sum of all previous delays. There will be a distinction between diagnostic and therapy delay.
Health system.
- Health professional who attended the patient at the first visit: Family doctor or specialist including which speciality.
- Teaching versus non-teaching primary care centre; urban versus rural ones and receiving hospital. – Hospital service that attended the patient in 
the various contacts during the diagnostic process.
- Number of consultations to the family doctor; to primary care emergency services; and to the specialist since the first contact. Consultations 
cancelled with family doctor and specialist.
- Complementary examinations done at the first visit: rectal exam; abdominal palpation; ultrasound; blood tests; X Ray films. Delay duration for 
each of the complementary tests. – Request and date of complementary tests at each contact prior to diagnosis. Results of complementary tests in 
order to exclude false negatives.
- Type of referral done by the family doctor to the specialist: preferential; programmed; emergency department. Diagnostic assessment and referral 
details in terms of presenting clinical picture, physical examinations.BMC Cancer 2007, 7:86 http://www.biomedcentral.com/1471-2407/7/86
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Discussion
We have minimized the selection risk by identifying study
patients from pathology reports instead of at admission
for surgery. In Spain the percentage of histological confir-
mation of CRC is greater than 96%. Nevertheless it is still
possible that some patients would not be included if they
had no biopsy results, due either to very advanced age or
severe ill-health. A potentially more important constraint
could be associated with information sources based on
medical records. Use of secondary information could
increase the risk of missing data for some variables. Nev-
ertheless, we consider that the patient interview process
will strengthen the comprehensiveness of information
obtained. Due to the inherent features of coordinated
studies it is very important to make a special effort to
standardize data collection, since multiple observers in
the different participating regions can introduce problems
of inconsistency.
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